利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

246 条记录 (耗时 0.029 秒)

    FLUOROCHEMICAL LIQUID AUGMENTED CRYOSURGERY
    32.
    发明公开
    FLUOROCHEMICAL LIQUID AUGMENTED CRYOSURGERY 失效
    使用FLUOR化学液体药品的FOR刀治疗的生产

    公开(公告)号：EP0835078A1

    公开(公告)日：1998-04-15

    申请号：EP96920456.0

    申请日：1996-05-21

    申请人： Temple University of the Commonwealth System of Higher Education

    发明人： STERN, Robert, G. ,  SHAFFER, Thomas, H. ,  WOLFSON, Marla, R.

    IPC分类号： A61B18 ,  A61B19

    CPC分类号： A61B18/0218 ,  A61B18/02 ,  A61B2018/00101 ,  A61B2018/0022 ,  A61B2018/0212 ,  A61B2090/378 ,  A61B2090/3925 ,  A61B2090/3933 ,  A61B2218/002

    摘要： This invention is a method for cryogenic treatment of a lesion (20) which comprises the steps of delivering a fluoro-chemical liquid to the lesion (20), placing at least one cryoprobe (26) into the lesion (20), and circulating a cryogenic fluid causing an ice ball (30) to form in a vicinity around the cryoprobe (26), wherein the ice ball (30) obliterates at least a portion of the lesion (20). The fluoro-chemical liquid is utilized to augment the cryosurgical procedure and is perfused or injected into and/or around the lesion site prior and/or during the application of a cryprobe (26) to the site. In one embodiment of the invention, the fluoro-chemical liquid acts as a contrast agent to enhance real time medical imaging of the lesion area and modifies the environment in and around the lesion area. In another embodiment of the invention, the fluoro-chemical liquid augments cryosurgical procedures by controlling the size and shape of ice balls (30) formed during the cryosurgical procedures. In this embodiment, a fluoro-chemical liquid with a properly chosen thermal conductivity and freezing point is utilized. Depending on the thermal properties chosen, the liquid either augments freezing of the target area and/or promotes thermal conduction to freeze larger areas, or limits the freezing of the target area and reduces thermal conduction. In an non-cryoprobe embodiment, the liquid is cooled to a temperature below the freezing point of the biological tissue. The cooled liquid is then infused into or around the cystic lesion to produce ablation.

    CONTROLLED RELEASE TABLET
    33.
    发明公开
    CONTROLLED RELEASE TABLET 失效
    与控释片

    公开(公告)号：EP0821582A2

    公开(公告)日：1998-02-04

    申请号：EP96908487.0

    申请日：1996-02-28

    申请人： TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION

    发明人： KIM, Cherng-Ju

    IPC分类号： A61K9 ,  A61K31 ,  A61K47

    CPC分类号： A61K9/2072 ,  A61K9/2031 ,  A61K9/2054

    摘要： A controlled release tablet including a pharmaceutical agent and an excipient. The excipient includes at least about 50 % of a water swellable polymer and a lubricant. The water swellable polymer is chosen such that the swelling rate of the polymer is equal to the dissolution rate of the swollen polymer. The excipient may also include such other ingredients as diluents, fillers, binders and other pharmacologically inactive compounds. The polymer is chosen with the pharmaceutical agent in mind such that the tablet will be fully dissolved at the same time that the last of the pharmaceutical agent is released.

    Improved container for liquid crystal cumulative dosimeter
    34.
    发明公开
    Improved container for liquid crystal cumulative dosimeter 失效
    VerbesserterBehälterfürkumulativeFlüssigkeitskristalldosimeter

    公开(公告)号：EP0775896A2

    公开(公告)日：1997-05-28

    申请号：EP97100850.3

    申请日：1991-12-19

    申请人： TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION

    发明人： Labes, M. Mortimer

    IPC分类号： G01K11/00

    CPC分类号： G01K3/04 ,  G01K11/165 ,  Y10S252/962

    摘要： A container (10, 10A, 10B, 10C, 10D, 10E) for a liquid crystal cumulative dosimeter including a resilient outer body (12, 12A, 12B, 12C, 12D, 12E) sealed to confine a first liquid crystal composition constituent (14, 14A, 14B, 14C, 14D, 14E) and a second liquid crystal composition constituent (16, 16A, 16B, 16C, 16D, 16E) and having at least one transparent section (20) to permit observation of the color of the confined composition, and a barrier (30) contained completely within and physically unattached to the outer body for separating the first constituent from the second constituent, whereby disruption of the barrier allows the first constituent to mix with the second constituent. The barrier is formed by using air bubbles. Methods of manufacturing the various containers shown and processes of using those containers are also disclosed.

    摘要翻译： 一种用于液晶累积剂量计的容器（10,10A，10B，10C，10D，10E），其包括密封以限制第一液晶组成物（14）的弹性外体（12,12A，12B，12C，12D，12E） ，14A，14B，14C，14D，14E）和第二液晶组合物成分（16,16A，16B，16C，16D，16E），并且具有至少一个透明部分（20），以便观察被限制的颜色 组合物和隔离物（30）完全包含在外部并且物理上不附着于外部主体，用于将第一成分与第二成分分离，由此破坏屏障允许第一成分​​与第二成分混合。 屏障通过使用气泡形成。 还公开了制造所示各种容器的方法以及使用这些容器的方法。

    TREATMENT OF PHYSIOLOGICAL CONDITIONS WITH DEGASSED PERFLUOROCARBON LIQUID
    38.
    发明公开
    TREATMENT OF PHYSIOLOGICAL CONDITIONS WITH DEGASSED PERFLUOROCARBON LIQUID 失效
    处理条件与生理学脱气全氟化碳液体。

    公开(公告)号：EP0650378A1

    公开(公告)日：1995-05-03

    申请号：EP93917159.0

    申请日：1993-07-14

    申请人： Temple University of the Commonwealth System of Higher Education

    发明人： SHAFFER, Thomas, H. ,  WOLFSON, Marla, R.

    IPC分类号： A61M31 ,  A61K31 ,  A61M1 ,  A61M3 ,  A61F7 ,  A61M5

    CPC分类号： A61M1/00 ,  A61F7/00 ,  A61M3/00 ,  A61M5/44 ,  A61M2202/02 ,  A61M2202/04 ,  A61M2202/0476 ,  A61M2202/0014 ,  A61M2202/0007

    摘要： This invention pertains to the use of a degassed perfluorocarbon ('PFC') liquid as a method of removing gas emboli from parts of a patient's body cava. Moreover, the invention can be used as a method of imaging parts of a patient's body cava. Furthermore, the invention can also be used as a way of delivering biological agents to parts of a patient's body cava which contain or are surrounded by gas emboli and/or which are to be imaged. In this invention, a degassed PFC liquid is delivered to a region within the patient's body cava which contains gas emboli and/or which is to be imaged. If gas emboli are present, the degassed liquid is permitted to absorb at least a portion of the emboli. Thereafter, the emboli-containing liquid is removed from the patient or is used as an imaging agent. If gas emboli are not present, the site is imaged before the degassed liquid reaches atmospheric equilibrium. Thereafter, the liquid is removed from the patient. Moreover, by mixing a biological agent with the degassed PFC liquid, the mixture can be used as a way of topically treating parts within a patient's body cava. Furthermore, by regulating the temperature of the degassed liquid, it can also be used as a way of hypo- or hyperthermically treating the patient.